论文部分内容阅读
目的:探讨替吉奥胶囊联合紫杉醇治疗晚期食管癌的近期临床疗效。方法:选取我院2015年收治的晚期食管癌患者45例作为研究对象,随机分为对照组(紫杉醇治疗)22例及研究组(替吉奥胶囊联合紫杉醇治疗)23例,比较两组患者临床疗效。结果:研究组治疗总有效率、肿瘤控制率显著高于对照组(52.2%vs 31.8%、78.3%vs 63.6%,P<0.05);两组患者毒副反应发生率组间比较差异无统计学意义(50%vs 43.5%,P>0.05)。结论:替吉奥联合紫杉醇治疗晚期食管癌近期疗效好于单纯采用紫杉醇治疗,并且毒副反应并未因药物联用而显著增加,具有较高的安全性,可作为临床治疗的优选方案加以推广使用。
Objective: To investigate the short-term clinical efficacy of Teglitazone combined with paclitaxel in the treatment of advanced esophageal cancer. Methods: Forty-five patients with advanced esophageal cancer who were admitted to our hospital in 2015 were selected and randomly divided into control group (paclitaxel treatment) and study group (treatment group with paclitaxel and paclitaxel) Efficacy. Results: The total effective rate and tumor control rate in the study group were significantly higher than those in the control group (52.2% vs 31.8%, 78.3% vs 63.6%, P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions Significance (50% vs 43.5%, P> 0.05). Conclusion: The effect of tegaserod combined with paclitaxel in the treatment of advanced esophageal cancer is better than that of paclitaxel alone. The side effects of taichi and paclitaxel have not been significantly increased because of the combination of drugs. It has high safety and can be used as the optimal solution for clinical treatment use.